PA
ALMS

PharVision Advisers’s Alumis Inc ALMS Stock Holding History

PharVision Advisers’s Portfolio ALMS Stock Details ALMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-20,693
Closed -$82.6K – 1055
2025
Q3 		$82.6K Buy
+20,693
New +$85.2K 0.05% 634

Other funds holding ALMS

ACMC
AyurMaya Capital Management Company Portsmouth, New Hampshire $148M AUM 24.4% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

PharVision Advisers's ALMS Position: Q4 2025 in Review

PharVision Advisers sold out of Alumis Inc (ALMS) in Q4 2025, closing a stake of 20,693 shares — an estimated $82.6K sold.

PharVision Advisers first reported a position in ALMS in Q3 2025 and held it in 1 quarter. The position peaked at $82.6K in Q3 2025. 134 funds tracked by Wall St. Rank hold ALMS as of Q4 2025.

  • PharVision Advisers reported no remaining Alumis Inc position as of Q4 2025 after selling out during the quarter.
  • PharVision Advisers sold 20,693 Alumis Inc shares in Q4 2025, an estimated $82.6K.
  • PharVision Advisers first reported a position in Alumis Inc in Q3 2025 and held it in 1 quarter.
  • PharVision Advisers's Alumis Inc position peaked at $82.6K in Q3 2025.
  • 134 funds tracked by Wall St. Rank held Alumis Inc as of Q4 2025.

Based on PharVision Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.